SPRB — SPRUCE BIOSCIENCES, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1683553 ·
Last close
$40.49
Market Cap
$116.37M
52W High
$127.90
52W Low
$38.06
ADV30
77,941
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -23,981,000 | -24,006,000 | 91,948,000 | 87,691,000 | 25,653,000 |
| Jun 2026 | 0 | — | -16,512,000 | -16,229,000 | 102,852,000 | 96,295,000 | 19,122,000 |
| Mar 2026 | 0 | — | -11,987,000 | -12,266,000 | 56,166,000 | 54,080,000 | 21,518,000 |
| Dec 2025 | 0 | — | -11,100,000 | -14,646,000 | 53,021,000 | 48,906,000 | 10,505,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-51,068,000
Investing CF
$-145,000
Financing CF
$128,236,000
CapEx
$-145,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-38.71
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-341,735,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-64,169,000
Pretax Income TTM
$-67,147,000
Interest Exp TTM
$2,978,000
Analysts
9
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -36,513,000 | -38,966,000 | 53,021,000 | 10,505,000 | 42,516,000 | -33,327,000 |
| Dec 2024 | 4,911,000 | -56,151,000 | -53,036,000 | 45,209,000 | 16,388,000 | 28,821,000 | -55,964,000 |
| Dec 2023 | 10,089,000 | -51,993,000 | -47,919,000 | 103,946,000 | 27,437,000 | 76,509,000 | -33,275,000 |
| Dec 2022 | 0 | -47,283,000 | -46,180,000 | 85,648,000 | 17,162,000 | 68,486,000 | -41,683,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-51,353,000
OpCashFlow TTM
—
Assets (Latest)
$102,852,000
Forward EPS
$4.49
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| UPB | Upstream Bio, Inc. | $115.10M | $2.10 | — |
| SCNX | Scienture Holdings, Inc. | $113.34M | $2.76 | — |
| AKBA | Akebia Therapeutics, Inc. | $111.18M | $0.40 | — |
| FHTX | Foghorn Therapeutics Inc. | $109.73M | $1.83 | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $124.92M | $4.33 | — |
News headlines (Yahoo Finance, 1h cache)
Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company
2026-11-18 00:02 · Yahoo
Spruce Biosciences Establishes Adrenyx Subsidiary to Develop CAH Treatment CRHX-101
2026-11-09 13:32 · Yahoo
Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
2026-11-09 13:00 · Yahoo
Spruce Biosciences Announces Separation of CRHX-101 (Formerly SPR-202) Program into Adrenyx Biosciences
2026-11-09 12:00 · Yahoo
Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-02 21:05 · Yahoo
Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference
2026-10-15 20:05 · Yahoo
Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting
2026-10-08 20:05 · Yahoo
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 20:05 · Yahoo
Spruce Biosciences stock gains after analyst backs regulatory progress
2026-08-27 12:09 · Yahoo
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026
2026-08-24 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.